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ABSTRACT: Localized 13C NMR spectroscopy provides a new investigative tool for studying cerebral metabolism. The
application of 13C NMR spectroscopy to living intact humans and animals presents the investigator with a number of unique
challenges. This review provides in the first part a tutorial insight into the ingredients required for achieving a successful
implementation of localized 13C NMR spectroscopy. The difficulties in establishing 13C NMR are the need for decoupling of
the one-bond 13C–1H heteronuclear J coupling, the large chemical shift range, the low sensitivity and the need for
localization of the signals. The methodological consequences of these technical problems are discussed, particularly with
respect to (a) RF front-end considerations, (b) localization methods, (c) the low sensitivity, and (d) quantification methods.
Lastly, some achievements of in vivo localized 13C NMR spectroscopy of the brain are reviewed, such as: (a) the
measurement of brain glutamine synthesis and the feasibility of quantifying glutamatergic action in the brain; (b) the
demonstration of significant anaplerotic fluxes in the brain; (c) the demonstration of a highly regulated malate-aspartate
shuttle in brain energy metabolism and isotope flux; (d) quantification of neuronal and glial energy metabolism; and (e) brain
glycogen metabolism in hypoglycemia in rats and humans. We conclude that the unique and novel insights provided by 13C
NMR spectroscopy have opened many new research areas that are likely to improve the understanding of brain carbohydrate
metabolism in health and disease. Copyright # 2003 John Wiley & Sons, Ltd.
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INTRODUCTION
Direct detection of 13C label provides a wealth of high-
ly specific information on metabolites and metabolic
rates,1–7 such as the measurement of resolved carbon
resonances of Glu and Gln in the brain,8,9 and the reliable
measurement of tissue glycogen10–18 and tissue glucose
content.19–24 Most of these studies have involved
the administration of a 13C-enriched precursor. When
the enriched 13C label is transferred to molecules in the
metabolic pathway, sensitivity can not only be increased,
but important information on metabolic pathways can
also be obtained. For example, recent studies showed that
the information content of 13C NMR spectroscopy can be
amplified considerably, such as the resolved observation
of GABA labeling in the human brain, as well as the first
detection of lactate labeling in normal human brain.8 In
addition to its importance in assessing metabolism
in intact brain, 13C NMR spectroscopy has become an
important and useful tool in assessing compartmentation
of metabolism in brain cells using extracts.25,26
In addition to its low sensitivity, 13C NMR spectro-
scopy is methodologically more challenging than 1H or
even 31P NMR spectroscopy. However, 13C NMR pro-
vides its own unique insight and advantages over 1H
NMR spectroscopy. The uniqueness of 13C NMR stems
mainly from its increased chemical shift dispersion,
which can, for example, be used in two-dimensional
NMR to increase spectral resolution following specific
labeling of the protein.27 As shall be elaborated further
below, 13C NMR spectroscopy in living tissue provides a
unique window on in vivo metabolism as it occurs. In the
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context of this review, we will consider mainly in vivo 13C
NMR spectroscopy of the intact brain, which places
specific requirements on the methodology. In contrast,
the important research done using 13C NMR spectro-
scopy of cell cultures and suspensions 28–30 requires
methodology that is equivalent to that of in vitro work
of body fluids and tissue extracts 31–34 and to some extent
isolated organs,35 since these studies are often performed
in high-resolution spectrometers with a test-tube-type set-
up, and usually localization is confined to everything that
is detected by the RF coil. Most in vivo 13C NMR
spectroscopy studies of intact organs have been per-
formed using the surface coil as the only means to
‘localize’ the signals.6,22,36–40 In contrast to the afore-
mentioned cell culture and suspension studies and related
important work, in vivo 13C NMR spectroscopy of intact
organs faces a number of problems that make its applica-
tion more challenging. Complete three-dimensional lo-
calization seems necessary in the brain to eliminate the
intense triacylglycerol resonances from the scalp and
other signals outside the brain, which adds to the chal-
lenges of in vivo 13C NMR. Localized 13C NMR spec-
troscopy thus is a novel investigative modality, the
methodological requirements for which are the focus of
the first part of this review.
LOCALIZED IN VIVO 13C NMR SPECTROSCOPY
OF THE BRAIN. A BRIEF HISTORY IN TIME
Localized in vivo 13C NMR spectroscopy has undergone
an impressive development in the past decade. A number
of historical developments leading to the metamorphosis
of this remarkable metabolic tool can be discerned. The
goal of this section is to provide a historical perspective
of the achievements of localized 13C NMR spectroscopy.
The first application of 13C NMR spectroscopy to a living
system was the metabolism of E. coli.28 The first in vivo
application of 13C NMR to the head was reported in
198637 and this early paper was admittedly struggling
with many technical problems. Most notably were the
limitations in localized shimming, which prohibited the
separation of the glutamine from the glutamate reso-
nances in vivo. In 1991–1992, it was shown for the first
time that sufficient 13C-labeled glucose can be adminis-
tered to humans to detect resonances from glutamate and
glucose.20,41,42 In retrospect, it is clear from the detection
of intense lipid signals in these and other early in vivo
spectra obtained from the head, that signals from outside
the brain were dominant.37,38,42,43 With the introduction
of full three-dimensional localization to 13C NMR spec-
troscopy of the brain,20,44 it rapidly became clear in
1991–1992 that the concentration of mobile lipids is
generally too low to be detected in vivo in the normal
brain (although this can be done in extracts45). Therefore,
the lipid resonances seen in 13C NMR spectra of the head
must be attributed to extracerebral fat tissue, such as
subcutaneous fat. The use of automated, localized shim-
ming (i.e. in vivo optimization of the main static magnetic
field, B0, such that it becomes largely independent of the
spatial coordinates46) of all first- and second-order terms
using FASTMAP dramatically improved sensitivity by
narrowing linewidths in 13C NMR spectra.47 These two
methodological advances contributed to the then rather
surprising observation that natural abundance signals
from brain metabolites such as those from myo-inositol
can be detected in vivo44 and the discovery that labeling
of glutamine can be detected in the brain in vivo.47,48 The
measurement of glutamine and glutamate turnover has
been recognized as a window to study cerebral metabolic
compartmentation.49–53 A few years later it was demon-
strated that the high demands of 1H decoupling are not
detrimental for the application of 13C NMR spectroscopy
at higher fields54 when using a novel RF coil design (see
below for further discussion). At about the same time, it
was also shown that three-dimensional localization based
on the 1H magnetization can be achieved in the brain in
vivo.55 Another, more recent development of in vivo 13C
NMR spectroscopy was the demonstration that localized
13C NMR detection of glycogen can be achieved,56
despite the relatively short relaxation times of the glyco-
gen 13C resonances. This advance led to the first non-
invasive detection of brain glycogen metabolism in the
rat17 and signals from glycogen were recently quantified
in the human brain as well,18 thereby opening a whole
new field for investigating brain metabolism. These
advances in NMR methodology and technology have
led to further insights into brain metabolism and placed
the 13C NMR method into the neuroscience theater to
provide a unique in vivo window on the brain. 13C NMR
spectroscopy holds promise to study a number of neuro-
chemical events that are otherwise inaccessible by non-
invasive means.
RELATIONSHIP TO OTHER NON-INVASIVE
MODALITIES. WHAT MAKES IN VIVO
13C NMR UNIQUE
The administration of a tracer, whether stable or radio-
active, and the ability to follow its metabolism in the
brain provides neuroscientists with tools to study in vivo
metabolism non-invasively. When using radiotracers,
label in different metabolic pools cannot be distin-
guished, which has led to the use of non-metabolizable
analogs, such as deoxy-glucose.
On the other hand, tracer studies can be performed using
stable isotopes. The metabolism of stable isotopes can be
followed non-invasively using NMR, although administra-
tion of the ‘tracer’ requires a higher isotopic enrichment,
for 13C, typically above 50% in the precursor pool.
Because NMR spectroscopy can be used to detect label
in different molecules and different chemical positions, it
offers the attractive possibility of following metabolism of
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the precursor, labeled at one or more specific positions. For
example, glucose can be labeled with 13C at the C1
position and flow of the label into metabolic pools further
downstream can be followed non-invasively. Applications
are predominantly focused on nuclei where a stable iso-
tope is present at low natural abundance, examples include
2H, 15N, 19F and 13C. The direct detection of the latter shall
be dealt with in this review.
The dominant method to measure cerebral glucose
consumption is by measuring the activity accumulated
in the phosphorylation product of a glucose analog, e.g.
the widely used autoradiography of deoxyglucose,57 or
the non-invasive fluoro-deoxy-glucose positron emission
tomography.58 In deriving the glucose metabolic rate
from the uptake of a glucose analog, the kinetics of
glucose transport is important and have been assessed
in several studies.59–61 In vivo NMR spectroscopy has the
capability of providing a direct, localized measurement
of brain glucose content non-invasively.20,21,24
Of course, sensitivity for NMR is low compared
with some radioactivity-based methods, and the relative
sensitivity of 13C NMR is even lower. Nonetheless,
despite the sensitivity disadvantage, as shall be discussed
in the second half of this review, 13C NMR spectroscopy
can provide unique insights into brain metabolism, albeit
at a low spatial resolution. Many consider a low sensi-
tivity and thus low spatial resolution a significant dis-
advantage. However, it is our belief that there are a
significant number of biomedical problems/questions
that can be uniquely addressed using in vivo 13C NMR
spectroscopy.
Ideally, an investigative method applied to biomedical
problems is fully developed and ‘mature’. Unfortunately,
the development of 13C NMR spectroscopy in vivo has
been limited to a handful of sites worldwide8,43,51,62 and
largely requires further development, as biomedical pro-
blems in general and neurochemical questions in parti-
cular develop. When considering these constraints on the
application of this method, it is clear that methodological
advances are probably required and expected when ad-
dressing important biomedical questions with 13C NMR
spectroscopy.
TECHNICAL ISSUES. THE CRUX OF IN VIVO
13C NMR SPECTROSCOPY
The application of 13C NMR spectroscopy to the brain in
vivo faces some challenges on the technical level that are
unique to the 13C nucleus. The reasons for 13C NMR
spectroscopy to be such a challenging modality stem
mainly from three roots:
* low inherent sensitivity and low natural abundance;
* exogenous administration of expensive 13C labeled
precursors;
* technically challenging methodology.
The first reason why 13C NMR spectroscopy is so
challenging lies in its relatively low sensitivity compared
with two other major nuclei used for in vivo NMR
spectroscopy, namely 1H and 31P. Although the inherent
sensitivity is comparable to that of, for example, 23Na
[gyromagnetic ratio (23Na)¼ 1.05(13C)], the problem
of relative sensitivity is compounded by the fact that the
13C isotope has a natural abundance on the order of 1%.
Hence in many cases, administration of exogenous 13C-
enriched precursors is not only mandatory but also
desired to obtain metabolic information. The administra-
tion of labeled precursors adds to the barrier, making a
broad application of this method more difficult compared
with 1H or 31P NMR spectroscopy, as it increases the cost
and experimental complexity. Even if the problem of low
sensitivity can be alleviated somewhat by the adminis-
tration of 13C-enriched substrate, considerable technical
difficulties remain, rooted in the desire to improve the
sensitivity. For instance, 1H decoupling and accurate
localization of the 13C NMR signals are necessary in
vivo. This section deals with the last of the aforemen-
tioned three challenges, first by examining the reverbera-
tions of the requirement to decouple the spectrum during
acquisition, second by discussing the localization re-
quirements, and lastly by reviewing issues related to
sensitivity and quantification.
RADIOFREQUENCY. THE LEGACY OF
DECOUPLING
Optimization of sensitivity is critical for successful in
vivo 13C NMR spectroscopy. To maximize the signal-to-
noise ratio and spectral resolution in 13C NMR spectra,
1H decoupling is generally applied during data acquisi-
tion, resulting in a simplified spectral pattern. The appli-
cation of rather intense RF power during acquisition
requires that the RF coil be capable of receiving the
13C NMR signal while transmitting 1H RF power. This
places several requirements on the RF console, RF coils
and RF filters, all of which shall be discussed below.
RF coil design
The need for decoupling results in two requirements for
RF coils: first, the 13C coil (operating at a frequency with
a wavelength approximately four times that of the 1H
frequency) should not interfere with the RF profile of the
1H coils. Second, the two RF circuits should be suffi-
ciently isolated electrically. While it is in principle
possible that surface coils with a resonance mode at the
1H as well as at the 13C frequency can be designed, these
designs typically result in a reduced RF efficiency at least
at one of the two frequencies, if not both. This may
have not been given much attention, since the perfor-
mance of the 1H circuit does not affect the sensitivity
or the direct-detected 13C NMR experiment per se.
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However, a less than optimal 1H coil design can result in
vastly increased RF power deposition and increased local
specific absorption rates (SAR).
Sensitivity requirements for 13C NMR have almost
invariably led to the use of surface coils for detec-
tion.36,63–65 The sensitivity of the experiment can be
further optimized with B1-insensitive pulses
44,65–67 to
alleviate the drawbacks of an inhomogenous RF field
for excitation. This discussion, therefore, will be focused
on the use of surface coils for 13C NMR spectroscopy.
Typically, surface coils consist of an inductor com-
bined with lumped capacitors. It is important to recognize
the fact that, at higher magnetic fields, the impedance of
the capacitor (1/i!C) is decreased at the 1H frequency and
approaches zero, which results in the RF of the 1H coil
being effectively blocked due to induced currents. The
increased flux blockage at higher field was especially a
problem for concentric 13C and 1H coils, previously used
at lower fields.20,44 To overcome this problem, the 13C
coil can be geometrically decoupled from the 1H coil.
Until 1996, several RF coil designs used a linearly
polarized, figure-8-type geometry (‘butterfly design’)
for the 1H decoupling coil, where the proton decoupling
RF field, B2, is parallel to the
13C coil plane. An inherent
shortcoming in all figure-8-type coil designs was the
rapidly decreasing B2 along the
13C coil axis, which
required excessive 1H RF power to decouple the entire
volume of the 13C coil and thus led to excessive local
SAR values close to the crossing point of the coil loops.
At the time, it was considered impossible to perform
broadband decoupled 13C NMR spectroscopy, especially
at high fields such as 4 T.
Recognizing that it was highly desirable to use a
quadrature decoupling coil that can reduce the RF power
requirements up to two-fold, it was demonstrated that two
surface coils can be used to generate a circularly polar-
ized RF field for 1H decoupling and imaging.54 The
resulting coil design (Fig. 1) was a combination of three
basic transmit/receive coils; one was a linearly polarized
13C coil that minimally affects the B2 field distribution of
the quadrature 1H RF field generated by the other two RF
coils. The end result of this design was that it allowed
efficient low-power decoupling at 4 and 9.4 T with
negligible performance loss on either channel.54
Such a half-volume quadrature 1H decouple coil design
was found to be more efficient in terms of local SAR than
previous coil designs for three reasons: first, the quad-
rature polarized coil has two-fold reduced power require-
ments for a given B1 than a linearly polarized coil.
Second, to achieve an optimal quadrature field in the 13C
coil sensitive volume, the two 1H coil loops were placed
as perpendicular as possible (Fig. 1). The increased
distance between the wires and the tissue reduced the
potential for so-called ‘hot spots’ of power deposition.
Figure 1. Cross-sectional view of a half-volume 13C–1H coil. From
Adriany and Gruetter.54 The 1H coil consists of two surface coil loops
with distributed capacitance. The geometric arrangement of the two
coils in conjunction with a quadrature hybrid generates a circularly
polarized RF field over the field of view of the smaller 13C surface coil,
which is placed above the intersection of the two 1H coils. The 13C coil
overlaps partially with each of the 1H coils, thereby minimizing the
voltage induced by the 1H coil in the 13C coil. The T1-weighted MDEFT
image180 of a human head is shown to illustrate the excellent quality and
relative homogeneity of the resulting 1H RF field
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Third, the resulting 1H RF field had a very modest
decrease along the y-axis. This novel coil design enabled
broadband decoupling with 30 W peak power using
WALTZ-16 at 4 T.54 With typical duty cycles of 10% in
vivo, this led to many applications being possible within
FDA guidelines at 4 T. Not surprisingly, this coil design
has been successfully adapted to 13C NMR spectroscopy
of the human brain with corresponding decreases in
power deposition over previous designs at 1.568 and
2.1 T69 and has been used in many other studies.70,71
The same coil design principle has been used for indirect
detection of 13C label in humans,62,70,72 where the larger
13C coils used for decoupling were driven in quadrature.
The same coil design was used in in vivo studies of the
rodent brain at 9.4 T,17,56,73 for inverse detection in the rat
brain at 9.4 T,74 and with a larger 13C quadrature coil
more recently also at 7 T in the rat.75
Double-tuned volume coils have the advantage of
providing coverage for the whole head and relatively
uniform RF fields. Demands on RF power, filter perfor-
mance and electrical isolation may critically increase
when using volume coils due to the higher RF power
required to generate a given B1 RF field. To avoid
substantial coil flux coupling, the coils or the coil fields
can be arranged in an orthogonal fashion.76 Volume coils
typically have a reduced sensitivity. These requirements
can be substantially alleviated by using, for example, the
TEM (transverse electromagnetic) resonator design,
which allows the generation of quadrature polarized RF
fields at both frequencies with minimal performance
losses on either circuit.77 Such coils have been used
with great success in 1H-detected 13C labeling studies
of the human brain.78,79
Console and RF filters
In addition to increased demands on an efficient RF coil
design, the inherent requirement to apply RF at the 1H
and at the 13C frequencies demands that the spectrometer
should be equipped with at least one additional broad-
band RF channel. This is a requirement that may not be
easily compatible with the design of MRI systems for
diagnostic purposes and hence may pose a direct tangible
barrier for clinical research applications using 13C NMR
spectroscopy.
Having the spectrometer capable of performing two-
channel broadband NMR spectroscopy does not guaran-
tee a successful application of 13C NMR spectroscopy.
Even when using a good RF coil design, RF coils rarely
provide sufficient isolation between the observe and the
decouple RF channel to allow 1H decoupling during
signal detection. Therefore, additional isolation is re-
quired, which can be achieved by the use of RF filters.
Two characteristics of RF filters must be considered,
namely the need to effectively filter unwanted frequency
bands, as well as the applicable RF power. In this context
it is important to recognize that some filters contain iron
cores, which are ferromagnetic and thus not useful close
to the magnet. In terms of RF power requirements, it is
important to state the required peak RF power under
which the filter must perform and the allowable contin-
uous wave power the filter must withstand. The recom-
mendation is to overdesign the peak RF power a filter can
handle to avoid the potential for filter breakdown.
Placement of the RF filter is equally important and in
many cases site-specific (Fig. 2). For instance, it may be
advantageous to place a bandpass filter at the input of
the RF amplifier to eliminate potential broadband noise
emanating from the modulator. In addition, it is typically
necessary to place bandpass filters at the output of the RF
amplifier, preferably after the RF has been passed into the
Faraday shield. Bandpass filters typically have a higher
insertion loss (1–2 dB) than low- or highpass filters and
thus can in principle be used for the decouple channel,
provided the RF power available is not limiting. On the
detection side, however, it is desirable to minimize
insertion losses, which can be achieved using low-pass
filters in the 13C channel. When using volume coils for
either channel demands on RF power, the requirements
on filter performance and electrical isolation may criti-
cally increase.
Figure 2. Placement of RF filters for direct-detected 13C NMR spectroscopy, adapted from
Adriany and Gruetter.54 The filters are designed to minimize 1H RF breakthrough at the 13C
(observe) channel. The 13C bandpass filter after the 13C pre-amplifier effectively renders the
pre-amplifier narrow banded
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Decoupling
Many 13C nuclei are directly bonded to protons. The
resulting magnetic coupling between the 13C nucleus and
1H nucleus results in a splitting of the 13C resonance into
multiplets separated by JCH Hz. The process of decou-
pling collapses the multiplets due to heteronuclear cou-
pling into singlets, thereby simplifying the spectra and
effectively increasing the sensitivity. Most 13C NMR
applications have relied on WALTZ decoupling of the
protons.80 Recently, it has been demonstrated that using
frequency-swept RF pulses as the basic building block,
such as the hyperbolic secant pulse,81 dramatically in-
crease the decoupling bandwidth. These decoupling
methods feature only modest increases in peak RF power
demand,82–84 while maintaining a favorable ratio of
cycling sideband intensity to center peak intensity.84
We recently demonstrated that broadband adiabatic 13C
decoupling was achieved at 9.4 T using such cycles at a
moderate peak B1/2 of 1 kHz.74
Specific absorption rates (SAR). RF power
is important
One potential risk to the MR examination is the fact that
the RF power absorbed by the tissue is converted to heat,
which can potentially lead to excessive heating of the
body and local tissue, resulting in damage. It is therefore
important to limit the RF power administered to the brain,
especially for human studies.
To minimize the SAR requires that the pulse sequences
and decoupling power are adjusted to operate at the
minimum power threshold at which sequence perfor-
mance is still acceptable. When using surface coils,
optimization of RF power is most reliably achieved
with an external reference sphere filled with a suitable
13C-labeled compound, such as formic acid, placed at the
coil center. Such an external standard for RF power
adjustment can also be an integral part of the external
quantification procedure (see below). Highly efficient and
accurate methods for adjusting the decoupling power
have been described.85,86
When measuring RF power it is of course important to
recognize that RF power lost in the cables, T/R switches
and filters will not reach the subject. Hence these factors
should be considered when calibrating the SAR monitor.
A practical approach is to measure the RF power at the
coil port with the spectrometer configuration set to what
will be used in the experiments. Additional factors that
will reduce the amount of RF power delivered to the
subject are: (i) the coil efficiency (which can be measured
by comparing the loaded vs the unloaded coil Q factor);
(ii) the power reflected by the RF coil (caused by, for
example, amplified RF noise transmitted outside the
bandwidth of the RF coil, acting as a bandpass filter);
and (iii) radiation losses, which are increasingly impor-
tant with increased RF frequency, i.e. B0. In general the
majority of the SAR is generated by the decoupling.
The Center for Devices and Radiological Health of the
United States Food and Drug Administration has stated
that studies exceeding SAR of 4 W/kg averaged over
15 min over the entire body or 3 W/kg averaged over the
head averaged over 10 min or 8 W/kg in any gram of the
head must be considered studies of significant risk
(www.fda.gov/cdrh/ode/guidance/793.html).
The first criterion for significant risk is rarely exceeded
in human studies using head volume coils or surface coils
and thus is less important. The second criterion is also
rarely exceeded in studies using surface coils, leaving the
last criterion as the most difficult to comply with.
LOCALIZATION. THE CHEMICAL SHIFT
DISPLACEMENT ARTIFACT
The full chemical shift range of most biologically inter-
esting 13C resonances is approximately 160–200 ppm
wide. Even when considering the four-fold lower
gyromagnetic ratio than 1H, this is a range that (in Hz)
exceeds the range for 1H resonances of main biological
interest (7 ppm) by at least a factor of six. Thus, chemi-
cal shift displacement error problems are important
factors to consider when wishing to localize 13C NMR
signals.
Is it necessary to localize NMR signals? For most
applications in the brain, the answer to this question
must be emphatically yes. In 1H NMR spectroscopy,
water suppression and the intense lipid signal from
subcutaneous fat cause dangerous artifacts that are likely
to obscure and degrade the signal from the brain. In 31P
NMR spectroscopy, for example, it is well known that
ATP and PCr concentrations in extracerebral muscle
(such as the signals from the temporalis muscle) are
vastly different than those in the brain and thus can
lead to inaccurate interpretation. In 13C NMR spectro-
scopy, water suppression is obviously not an issue and for
some resonances the lipid signals may not be a significant
problem. Non-localized 13C NMR has found important
applications, especially when considering the need for
signal (which undoubtedly is reduced when using loca-
lization methods) and experimental simplicity.39,87–89
However, for some resonances, such as glucose, lactate,
glutamate and especially glycogen, the concentration in
extracerebral tissue can be significant.
Therefore, localization is important for 13C NMR
spectroscopy of the brain, because the frequently em-
ployed technique of subtracting, for example, a pre-
infusion natural abundance 13C spectrum has several
drawbacks. Among the potential problems of subtracting
a pre-infusion spectrum are the reduced sensitivity, in-
creased measuring time, the susceptibility to motion
artifacts and small changes in linewidth over the rather
long measuring times.
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Spatial localization does not depend on chemical shift
when using the one-dimensional surface-spoiling gradi-
ent63,90 or spectroscopic imaging,91,92 which is an elegant
technique to solve the chemical shift displacement pro-
blem when many transients can be acquired.93 The low
spatial resolution may require dedicated solutions to
minimize Gibbs ringing from superficial fat signals, and
several approaches have been described.94,95
Nevertheless, one of the challenges of localized 13C
NMR is the localization error induced with slice selection
techniques due to the demanding 13C chemical shift
range. In the following, we will concentrate on the
various methods for full three-dimensional localization
of 13C NMR signals using gradient-based methods.
Direct localization using slice-selection
The use of direct localization of 13C has been discounted
on the basis of the large chemical shift requirement
leading in general to increased demand on the RF power
through the need for an increased RF bandwidth. In some
cases, even when the demands on the RF bandwidth can
be met, the required gradient strength may very well be
limiting, because of the lower gyromagnetic ratio . The
following example illustrates this case: true localization
of the entire 13C chemical shift range including the
carboxyl resonances at around 180 ppm and the lactate
methyl resonance at 20 ppm requires a range of 160 ppm
to be covered, equivalent to a frequency spread of
1700 Hz/T B0 field. To maintain the chemical shift
displacement error below 10% of the voxel dimension,
the bandwidth of the RF pulse thus has to be 17000 Hz/T.
When localizing a slice of, for example, 4 cm, the
gradient strength must be 4250 Hz/cm, which corre-
sponds to a gradient strength of 40 mT/m per Tesla B0,
because the  of 13C is four-fold smaller than that of 1H.
For low magnetic fields such as 1.5 T, a gradient strength
of 60 mT/m is required and this is pushing the envelope of
what is currently possible, even more so at higher B0.
However, when contemplating the large chemical shift
range of 13C, it is worth considering that the chemical
shift range that needs to be covered for specific applica-
tions may be much smaller. Such reduced chemical shift
dispersion is summarized for several metabolites in
Table 1. For example, all the inositol resonances are
observed within 3 ppm96 and it is obvious that the
chemical shift displacement error for myo-inositol is
small, even when using direct localization. The first
three-dimensional localization of 13C NMR signals was
achieved using ISIS localization on the 13C z-magnetiza-
tion,48 used for the first direct measurement of brain
glucose C1 in the human brain.20 In addition, directly
localized 13C NMR spectroscopy was used for the first
detection of the natural abundance signals of small
molecules, as illustrated with myo-inositol.44
Polarization transfer
Localization on the 13C magnetization using ISIS must be
considered a valid localization method for a restricted
spectral region. However, when using the 13C longitudi-
nal magnetization for localization, signal enhancements
are commonly achieved using the nuclear Overhauser
effect (NOE), which has a theoretical upper limit of a
three-fold enhancement of the 13C signals. However, for
resonances with sufficiently long T2, such as those of
most brain metabolites as judged from their narrow line
widths of a few Hz,47 it is feasible to use polarization
transfer to recover the maximal sensitivity gain of a four-
fold enhancement and to localize on the 1H magnetiza-
tion, thereby greatly reducing the chemical shift displa-
cement error due to the much smaller chemical shift
range (Table 1). Heteronuclear polarization transfer com-
bined with localization on the proton magnetization, as
proposed earlier,97 was shown to minimize the chemical
shift displacement error in 13C MRS of the human brain
to a level beyond concern even at 4 T.55 To minimize the
number of pulses needed for generating the in-phase 13C
signal enhancement and to minimize phase distortions in
the spectrum, distortionless enhanced polarization trans-
fer, DEPT,98 was used. Another alternative was IN-
EPT,69,99 which required more RF pulses compared
with DEPT, having more potential for signal loss in
inhomogeneous RF fields. Because of the number of
RF pulses used, polarization transfer sequences tend to
be more sensitive to B2 inhomogeneities such as those
present when using surface coils. However, surface coils
were used to optimize sensitivity as in almost all 13C
studies, and the polarization transfer sequence had to be
carefully optimized for the volume of interest, which
was shown to be possible when using localized pre-
calibrations of decoupler and transmitter RF power.55
Table 1. Chemical shift ranges for 13C MRS per Tesla (expressed in Hz/T) including the range of the corresponding
coupled 1H resonances
Compound class Chemical shift range (ppm) 13C Frequency range (Hz/T) 1H frequency range (Hz/T)
Glycogen/glucose (all) 101–61 430 94
Myo-inositol (all) 76–72 43 34
Amino acids (CHn) 56–22 363 85
Amino acids (CH) 56–53 32 20
Lipids (CHn) 131–14 1248 196
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As a result, a high sensitivity can nevertheless be
achieved, especially when the VOI dimensions are small
enough that RF variation across the VOI can be ne-
glected.54,55 While excellent sensitivity was demon-
strated with the localized detection of natural
abundance myo-inositol, scyllo-inositol, glutamate, taur-
ine, glucose, glutamine and NAA signals,21,54,55,96
further gains were expected when incorporating adiabatic
pulses into the pulsed polarization transfer sequence,
which was shown to improve reliability and sensitiv-
ity.8,100 When performing direct-detected 13C NMR
spectroscopy, the 13C coil is typically smaller than the
1H coils and thus the 13C part of the polarization transfer
is more prone to signal loss. Replacing the standard 90–
–180– section of the 13C channel in DEPT with a
segmented BIR-4101 pulse resulted in greatly minimized
effects of RF inhomogeneity on the acquired signal.8,102
Such a sequence is shown in Fig. 3.
The broadband localization achievable with polariza-
tion transfer methods has resulted in localization of all
amino acid resonances in the human brain [Fig. 4(A)] as
well as in efficient broadband localization in the rat brain
for the first time [Fig. 4(B)], indicating complete elim-
ination of extracerebral lipid signals.
Figure 3. Localization using a semi-adiabatic DEPT se-
quence including coherence elimination by gradient dephas-
ing. From Henry et al.102 Localization is performed on the 1H
z-magnetization using ISIS, complemented with outer vo-
lume suppression (OVS). The 1H part of the coherence
generation was achieved using standard hard pulses, with
the last pulse flip angle set to 45 to allow for the simulta-
neous detection of all CHn carbons. The two 90
––180–
sequence was replaced by a segmented 0 BIR-4 pulse,
rendering the performance of the sequence much less
susceptible to the spatial variation of the 13C RF field,
especially when using surface coils. The spoiling gradient
(spoil) dephases unwanted coherences excited by the 1H
pulses when they deviate from their nominal flip angles
indicated. The delay  is determined by the heteronuclear
J coupling, JCH, which ranges in vivo from 127 to 167 Hz
74
Figure 4. Examples of direct-detected 13C NMR spectroscopy from the brain. (A) 13C NMR detection of label
incorporation into mostly cytosolic amino acids at 4 T, from Gruetter et al.9 Shown is a representative spectrum
obtained from a 45 ml volume in the human visual cortex during an infusion of 67%-enriched [1-13C]glucose. In
addition, resonances resulting from homonuclear 13C–13C coupling were readily detected at the positions of all
glutamate resonances (indicated by the brackets). Processing consisted of a mild Lorentz–Gauss apodization (3 Hz)
and the spectrum is shown without baseline correction. (B) In vivo 13C NMR spectra from a 400ml volume in the rat
brain, acquired using the modified DEPT sequence depicted in Fig. 3 during an infusion of 70%-enriched
[1,6-13C2]glucose, from Henry et al.
102 Processing consisted of zero-filling, 2 Hz Lorentzian-to-Gaussian resolution
enhancement and fast Fourier transform. No baseline correction was applied. Note the complete absence of the lipid
signals over the entire spectral range. Resonance assignments are as follows: Glu C2 at 55.6 ppm; Gln C2 at 55.0 ppm;
NAA C2 at 54.0 ppm; Asp C2 at 53.7 ppm; NAA C3 at 40.5 ppm; GABA C4 at 40.45 ppm; Asp C3 at 37.6 ppm; GABA
C2 at 35.3 ppm; Glu C4 at 34.2 ppm; Gln C4 at 31.7 ppm; Glu C3 at 28.0 ppm; Gln C3 at 27.7 ppm
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Three-dimensional localization of the 13C NMR
signals of glycogen
Clearly, the chemical shift displacement error can be
minimized by using the 1H z-magnetization for localizing
the signals for 13C NMR detection. However, methods
such as those discussed in the previous section are not
applicable in situations where T2 is very short. Unfortu-
nately, for some compounds such as glycogen, the T1 and
T2 are relatively short. This is especially true for T2 that is
short relative to the delays required to generate polariza-
tion transfer, resulting in substantial signal loss. There-
fore, it is impossible to realize the full sensitivity gains of
the polarization transfer technique. Nevertheless, it has
been pointed out that in muscle the signal gains with a
frequency-tailored INEPT sequence are comparable to
what can be achieved by proton decoupling and NOE
generation (SINEPT).15,103 While the SINEPT tech-
nique relies on performing the polarization transfer on-
resonance and without refocusing the J evolution, thereby
minimizing the T2-losses, the method remains in princi-
ple susceptible to changes in T2, which have been
reported to occur depending on the glycogen molecule
size and temperature.104 Unfortunately, the potential
four-fold signal gain is reduced by the short T2 of
1H
and 13C signals on the order of 5 ms.15,104,105 Given the
uncertainty of potential changes in transverse relaxation
times,104 a robust method that is capable of achieving
three-dimensional localization of the glycogen signal
without transverse coherence generation was considered
advantageous.
The method developed for the localized measurement
of glycogen relies on outer-volume suppression, achieved
with slice-selective inversion recovery nulling of the
magnetization in two slices parallel to B0 and perpendi-
cular to the RF coil (Fig. 5) in conjunction with nominal
90 pulses applied along the six slices parallel to the
volume-of-interest. In the brain (see below) such locali-
zation was crucial to minimize potential contamination of
the detected signal with signals from extraneous muscle,
especially in the rat. The performance of the sequence
was validated from the post-mortem rapid elimination of
glucose and glycogen in the brain, which is rapid com-
pared with muscle [Fig. 6(A)], as well as from the
elimination of subcutaneous lipid signals, as shown for
the human head in Fig. 6(B).
SENSITIVITY. UNEARTHING TINY SIGNALS
Because the detection of 13C label is inherently insen-
sitive, generally every effort is made to improve the
sensitivity. In this section, we focus on the sensiti-
vity gains achieved with increased magnetic field B0,
direct vs. indirect detection, choice of RF coil and
shimming.
Figure 5. Localization of 13C NMR spectroscopy using OVS only, from Choi et al.56 The
localization of the magnetization starts with two adiabatic pulses that invert the z-
magnetization in slabs along x adjacent to the voxel. This inverted z-magnetization
approaches zero during the delay TI and when it is approximately minimized, a standard
OVS sequence along all three dimensions with nominal 90 flip angles applied. Just before
the adiabatic excitation pulse, an optional inversion pulse is applied on alternate
scans, which together with the concomitant y-gradient and appropriate phase cycling
selects a slice along y (parallel to the 13C coil plane) as in one-dimensional ISIS. Reproduced
with permission from Mag. Reson. Med. Copyright# 2000 John Wiley & Sons, Ltd.
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Effect of higher magnetic fields, B0
It is well-known that increasing the static field B0
increases the sensitivity of NMR detection.106 The in-
crease in sensitivity for non-loading samples has been
reported as being an exponential function of B0, which
can be written as
S=N / B0 ð1Þ
From theoretical considerations, it is clear that the
signal S increases with B0
2, hence  must be 2 or lower,
amounting to an upper limit for the gains in sensitivity
achievable due to increases in B0 alone. Even when the
noise present in the RF coil is the dominant source of
noise, its root-mean-square amplitude may increase with
frequency (B0) and it is generally accepted that in this
case ¼ 1.75. For in vivo spectroscopy, however, the
sample is the most dominant source of noise and thus the
noise detection efficiency increases with frequency and
thus the sensitivity increase with B0 is closer to linearity
with 1. Because the sample may not be the dominant
source of noise, it is plausible that in vivo  may lie
somewhere between 1 and 1.75. In practice  is probably
closer to the former. In this discussion it was assumed that
resonance linewidths and relaxation times are very simi-
lar between the different field strengths. An increase in
resonance linewidth can offset some of the sensitivity
gains, as can an increase in longitudinal relaxation time,
although the latter effect influences sensitivity only with
the square-root of the T1. Lastly, increased spectral
resolution can result in increased sensitivity due to the
decreased signal overlap. Spectral overlap may in general
not be a problem for direct-detected 13C NMR spectro-
scopy, but resolution of the spectral region of the C2 of
amino acids and the overlap between GABA C2 and
glutamate C4 stand to gain from increased spectral
resolution. In practice, it is very difficult to determine
the precise value of , but it is possible to state the
sensitivity gains achieved over previously published
results.
Figure 6. Validation of the localization of 13C NMR signals using OVS (Fig. 5).
(A) Twenty minutes after termination by KCl injection, glucose and glycogen
resonances from extracerebral tissue are still observed in the post-mortem rat
(top), whereas upon application of the three-dimensional localization method
these signals were reduced to the noise level (bottom trace). Reproduced with
permission from Choi et al.17 (B) In the human brain, where such post-mortem
studies are not applicable, the efficiency of the adapted sequence was verified
from the more than 100-fold suppression of the superficial lipid signals. From
Oz et al.18 Copyright # 2003, with permission from Elsevier
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Some studies have suggested that the sensitivity gains
at lower frequencies may be supralinear,107 indicating
that the RF coil contributes significantly to the noise. In
this case, the use of superconducting RF coils may
potentially yield additional sensitivity gains,108 as is
increasingly being realized for high-resolution NMR of
solutions. It is of interest to note that polarization transfer
from hyperpolarized compounds has been recently used
with specific compounds to image blood flow.109 This
points to the potential utility of hyperpolarization for 13C
to enhance sensitivity, although how this will be achiev-
able is at present not clear.
Direct vs indirect detection
A study of the sensitivity of 13C NMR spectroscopy in
vivo would be incomplete without pointing out the two
principal detection methods available, namely direct and
indirect detection of 13C label. Direct detection of the 13C
signals takes advantage of the large chemical shift dis-
persion of the 13C nucleus. In addition, the spin systems
of the 13C nucleus are simpler, provided 1H decoupling is
applied.55 However, the increased specificity of direct
detection comes at the price of a substantial loss of
sensitivity.72 For example, the signal-to-noise ratio from
an equimolar concentration of 13C at a given static field
B0 is much lower for
13C than the corresponding 1H
signal in vivo. In theory the signal is 3 stronger for 1H
(64-fold, which in the literature is often confused with the
gain in sensitivity). However, under conditions of full
sample loading (noise ) this is reduced to a 2 (16-
fold) sensitivity gain. Polarization transfer reduces the
relative sensitivity gain to . In many cases, such as
glutamate, glutamine and aspartate, the resonances in the
1H spectrum are coupled to other 1H, resulting in often
complex resonances of appreciable width on the order of
20 Hz, as is the case for the -proton of glutamate. In
contrast, the 13C resonances have linewidths on the order
of a few Hz,47 and this can translate into a further
reduction of the estimated sensitivity gain of approxi-
mately two-fold. In addition, the multiplicity of the CHn
groups enhances the sensitivity of 1H detection. Thus the
sensitivity gain is estimated at 2n:1. These estimated
sensitivity gains may in some cases be offset by the
limited spectral resolution for protons. Given these real
advantages in sensitivity, it is attractive to exploit the fact
that 1H nuclei in close chemical proximity to a 13C
nucleus are coupled through the heteronuclear J cou-
pling. With appropriate ‘spin gymnastics’ this coupling
can be exploited to extract the signal from these protons
by eliminating the signal from protons that are not
coupled to 13C.74,78,110–113 The ensuing ‘13C-edited’ 1H
spectrum stands to benefit from the improved sensitivity
of the proton. It also stands to suffer from a major
shortcoming of 1H NMR spectroscopy, namely the lim-
ited spectral dispersion, as the corresponding chemical
shifts in biomedical applications reside in a 10-fold
reduced bandwidth compared with carbon, and additional
efforts such as two-dimensional spectroscopy may be
required to achieve adequate spectral resolution.99
The spectral resolution in 1H NMR spectroscopy is
especially limiting at low magnetic fields, such as the
widely deployed magnetic field of 1.5 T, which does not
allow the accurate separation of the resonances of gluta-
mate and glutamine. When increasing the magnetic field
some of these limitations can be overcome due to
improved spectral dispersion,114 allowing the detection
of resolved signals from 13C labeled glutamate and
glutamine by 1H NMR spectroscopy.74 Figure 7 shows
that in 1H NMR spectra the resolution of a number of
resonances is limited even at 9.4 T, when comparing with
the resolution in the 13C NMR spectrum [Fig. 4(B)]. A
recent study at 7 T recently confirmed that the spectral
resolution decreased with lower field in the 1H spectrum
compared with direct-detected 13C NMR.75 Nonetheless,
the C2 resonances of glutamate and glutamine are not
easily separated in the 1H NMR spectra (Fig. 7), whereas
at 4 T (Fig. 4),8,9 and to some extent at 1.5 and 2.1 T, the
C2 of glutamate and glutamine are readily separated in
direct-detected 13C NMR spectra.43,47,69 In addition,
direct detection offers the potential to detect 13C–13C
couplings (Fig. 4),56,102,115 containing important meta-
bolic information.116,117
RF coil sensitivity considerations
When using surface coils it is advantageous to use
adiabatic RF pulses to overcome the problems aris-
ing from inhomogenous RF fields, which have been
used in a number of studies for 13C NMR spectro-
scopy.8,17,18,20,44,65,66,69,102,118 In principle it may be
desirable to have a homogenous RF field covering the
entire brain, as is being widely used for head imaging on
conventional MR scanners. When compared with surface
coils, the volume coils require increased RF power since
the RF power is distributed into a larger volume.106
Increased RF power implies decreased sensitivity from
the reciprocity principle. It is not surprising that volume
coils typically are two to three times less sensitive than
surface coils with optimized dimensions, even when
considering the most efficient coil design. This sensitivity
loss can be partially compensated by imaging the 13C
label indirectly,79,99,119 which may require simplified
models of brain glutamate metabolism (see below).
Shimming
Even though the effect of B0 inhomogeneity on the
linewidth of a 13C resonance is reduced four-fold com-
pared with that of 1H, shimming remains an important
issue: the low sensitivity of 13C NMR typically precludes
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the measurement of signals from small volumes, leading
to comparatively large volumes. The measurement of
substantially larger volumes probably results in the
need for adjusting the currents in the second-order shim
coils, which can be achieved using quantitative shim
methods.47,120,121 The need to adjust second-order shim
coils can be appreciated from the fact that the spatial
distribution of the B0 field of second-order shim coils
results in significant signal intensity being distributed in
the wings of the resonance (Fig. 8). Such signal distribu-
tion can be easily missed in peak integration or even
peak fitting at low signal-to-noise ratios, which are
typical for in vivo 13C NMR spectroscopy, or when using
even modest resolution enhancement. Shimming with
second-order shim coils typically has only a modest
effect on the full-width at half-maximum of the reso-
nance. Nonetheless, a significant fraction of the total
signal in the wings is shifted under the main resonance,
thereby reducing the potential for quantification errors
and increasing the sensitivity of the experiment further.
These effects are expected to be of increased importance
with increased B0. In summary, it will be important to
adjust second-order shim coils to harness the full sensi-
tivity gains at higher field.
QUANTIFICATION METHODS FOR IN VIVO
13C NMR SPECTROSCOPY
This section focuses on the methods available to calibrate
the in vivo signal intensity. How to measure the signal
intensity using peak fitting, integration or other compu-
tationally even more involved methods is not part of this
review. The reader may be interested in a companion
article in this issue which considers issues of peak
intensity measurement.122
Internal reference methods
Internal reference methods have become the method of
choice for quantification of 1H NMR spectroscopy. These
methods use either referencing to the signal of a com-
pound measured in the spectrum, such as creatine, or
Figure 7. Illustration of the information content achievable in vivo by
1H-detected 13C NMR at 9.4 T. The 1H NMR spectrum was obtained
from a 130 ml volume in the rat brain in the first 1 h of glucose infusion
showing resonances coupled to 13C only, from Pfeuffer et al.74 The
improved sensitivity allowed the detection of label incorporation into
alanine C3 (Ala). Natural abundance signal is detected for creatine
(Crtot) and NAA. Reprinted from Magn. Reson. Med. Copyright #
1999 John Wiley & Sons, Ltd.
Figure 8. Effect of shimming on lineshape and width.
Shown is the effect of a second-order shim coil (yz) on the
field distribution in a cubic volume. Upon elimination of this
term (by shimming), the intensity in the wings is moved
underneath the central peak indicated by the arrows,
thereby increasing sensitivity and reducing potential quanti-
fication errors
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referencing to tissue water. These methods are not easily
applicable for 13C NMR spectroscopy. The main reason is
that 13C NMR spectra of the brain typically lack a signal
from a natural abundance compound that is present in
high concentration, although it appears that, especially at
high fields and longer acquisition times, the signal of
some brain metabolites might be sufficient, this has been
used by some investigators. However, these signals are on
the order of 0.1–0.2mmol/g in 13C concentration and the
signal-to-noise ratio of such reference measurements is
typically low, especially at low fields. Errors in the refer-
ence measurement are expected to propagate into the
quantification of the 13C label in the 13C NMR spectrum.
External reference methods
Because of the complexity of the 13C NMR measure-
ments and the frequent use of the surface coil as trans-
ceiver, the external reference method has become an
important tool to quantify 13C label in the brain. The
method is based on the idea of repeating the identical
NMR experiment (under identical experimental condi-
tions as in vivo) in a phantom containing an aqueous
solution of a reference compound (typically identical to
that being measured, such as glucose, glycogen, etc.) of
known concentration. The principle of the external re-
ference method is illustrated in the scheme in Fig. 9. The
RF power is adjusted based on the reference signal
provided at the 13C coil (see above) and corrections for
the effect of coil loading on the signal and of differential
relaxation effects are measured and taken into account in
the quantification. A major advantage of this method is
that, by repeating the reference experiment under iden-
tical conditions (i.e. applying RF at the identical chemical
shift with an identical B1 at the coil center), some
imperfections are inherently corrected, such as off-
resonance effects in the sequence and effects of inhomo-
genous B1.
Quantification of brain metabolites using
natural abundance 13C NMR of the brain
Studies using natural abundance 13C NMR certainly are
not expected to compete with 1H NMR measurements of
the respective compound; however, they prove invaluable
in estimating concentrations, which can aid the quantifi-
cation of the 1H NMR spectrum.88,123 For example, the
difficulty in detecting the natural abundance signal of
glutathione (GSH) indicates a concentration below
3 mmol/g in agreement with 1H NMR quantification124
and, similarly, the concentrations of taurine, aspartate and
GABA are expected to be below 2 mmol/g.
From the sensitivity and the quantification of the
localized 13C NMR signals of glucose in the human
brain,20 it was suggested that signals from natural abun-
dance myo-inositol should be detectable at 2.1 T. At the
time, the only compounds measured by natural abun-
dance 13C NMR were glycogen in muscle 125 and liver,11
creatine in skeletal muscle14 and subcutaneous lipid
signals, all of which are present in quantities of tens of
mmol/g or above. Indeed, it was shown early on that
quantification of natural abundance myo-inositol was
Figure 9. Scheme of the external reference method. The in vivo
experiment is scaled by the reference intensity from, for example,
99% 13C-formic acid (FA) placed at the 13C coil center to correct for
differences of the effect of sample loading between the in vivo and
the reference experiment. The signals are further corrected by the
correction factor CF that takes into account the relaxation effects
on the signal (T1, T2 and NOE) in vivo, CF
in vivo, and in the phantom,
CFref, to yield the corrected signal intensity Icorr. From the known
concentration in the phantom the in vivo concentration can be
determined, as follows:
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possible.44 Improvements in sensitivity and magnetic
field strength have permitted the localized quantification
of glucose,21 as well as glutamine, glutamate, N-acetyl-
aspartate (Fig. 10 ) and elevated scyllo-inositol.96
APPLICATIONS: FINDINGS FROM LOCALIZED
13C GLUCOSE LABELING STUDIES OF THE
BRAIN
The detection of signal from natural abundance com-
pounds in the brain certainly represents a useful comple-
ment to in vivo quantification by 1H NMR spectroscopy,
albeit of limited practical value. The real power of 13C
NMR spectroscopy is more obvious when considering the
administration of 13C labeled precursors such as glucose
to follow the redistribution of the label in metabolic
products of glucose consumption. Localized 13C NMR
spectroscopy to date has provided insights into brain
metabolism in vivo. In addition to measuring the turnover
of glutamate and glutamine, other observations provided
by localized 13C NMR spectroscopy include: (i) the
demonstration of reversible Michaelis–Menten kinetics
of glucose transport in human brain, and that a brain
glucose close to zero is the point where cerebral blood
flow increases during hypoglycemia; (ii) the measure-
ment of brain glycogen metabolism during hypoglycemia
in animals, demonstrating that brain glycogen is a sig-
nificant source of fuel during hypoglycemia; (iii) the
detection of very slow brain glycogen metabolism in
the human brain; (iv) the revelation that pyruvate carbox-
ylase flux (anaplerosis) is substantial in the in vivo human
brain; (v) the demonstration that glial metabolism is
significant at rest and mostly oxidative in vivo; (vi) the
measurement of the malate-aspartate shuttle flux as a
major controlling step in brain oxidative metabolism and
isotope flux; and (vii) the observation that glutamate
metabolism is affected by physiological focal stimulation
in human brain. In addition to these studies, localized 13C
NMR spectroscopy was used to detect in vivo GABA
labeling as well as significant lactate metabolism in the
resting, healthy brain.8,74
These observations make it clear that localized 13C
NMR spectroscopy provides a unique window on in vivo
brain metabolism, with a chemical specificity and diversity
of potential measurements not possible by other methods.
Some of these achievements shall be highlighted below.
GLUCOSE TRANSPORT
In principle, glucose concentrations can be measured
using 1H NMR spectroscopy.21,126 However, for a CH
group with homonuclear J-coupling, the sensitivity ad-
vantage compared to 13C is expected to be only two- to
three-fold as discussed above. The proximity of the 1H
resonance of glucose H1 to water adds to the difficulty in
measuring brain glucose using 1H NMR spectroscopy.127
In cases where metabolism is followed by 13C NMR, it
may be advantageous to measure brain glucose content as
well. Unless labeled glucose is injected directly into the
brain, the administered 13C label must cross the blood–
brain barrier before it can be metabolized by the brain
cells. Aside from lactate and possibly glycogen,17 brain
glucose is the only sizable kinetic pool that is capable of
influencing the labeling kinetics of pyruvate and thus
ultimately of acetyl-CoA. Therefore, precise knowledge
of the size of the brain glucose pool and its physical
distribution space is important for the derivation of
absolute metabolic fluxes from, e.g. glutamate labeling
Figure 10. Localized 13C NMR detection of natural abundance reso-
nances in the human brain. The glucose resonances detected during
hyperglycemia are indicated by the vertical dashed lines and identified by
the comparison with the glucose phantom (bottom trace). In addition to
glucose and myo-inositol, resonances from glutamate, glutamine and N-
acetyl-aspartate were also discernible. From Gruetter et al.21
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curves.6,22 It has been shown that steady-state glucose
transport kinetics can be derived from the relationship
between brain and plasma glucose, which can provide
insights into the kinetics of the brain glucose pool.20–22,24
Glucose is the single most important substrate for
normal function, and the brain relies on a continuous
import of glucose from the blood, which must occur
across the blood–brain barrier. Glucose transport rates
into the brain are thus indicative of the maximal sustain-
able rate of glucose consumption, CMRglc.
Traditionally, glucose transport kinetics has been ana-
lyzed with a model of brain glucose transport that was
based on standard Michaelis–Menten kinetics. However,
Michaelis–Menten kinetics is based on the assumption
that initial rate of unidirectional product formation is
measured, e.g. immediately after substrate and enzyme
have been combined. This experimental condition would
require the elimination of the brain glucose, which is
difficult to achieve without interfering with normal brain
function. Hence it is reasonable to expect that reversible
Michaelis–Menten kinetics is more appropriate in de-
scribing brain glucose transport. Such a model has been
proposed,21,128 and it was shown that one implication of
the reversible model of brain glucose transport is that the
relationship between brain and plasma glucose is linear.21
Many measurements of brain glucose content as a func-
tion of plasma glucose have in the meantime corrobo-
rated the observation that brain glucose concentrations
are a linear function of plasma glucose,24,115,129,130 and
such a case is illustrated for two different anesthetic
regimes, -chloralose and pentobarbital in Fig. 11(A).
These studies indicated that decreased electrical activity
and thus decreased energy metabolism resulted in in-
creased brain glucose concentrations. The increment in
Figure 11. Brain glucose transport kinetics from the measurement of
the brain glucose content as a function of plasma glucose concentra-
tion. (A) Demonstration of a linear relationship between brain and
plasma glucose concentrations, as well as the effect of increased
anesthesia (decreased electrical activity) on brain glucose content in
vivo. From Choi et al.115 (B) Comparison of 13C NMR quantification
with 1H NMR quantification of brain glucose concentrations during
hypoglycemia. From Choi et al.24
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brain glucose was consistent with an approximately two-
fold reduction in brain glucose utilization. The data
furthermore indicated that during deep pentobarbital
anesthesia (a condition known to cause isoelectricity),
the brain glucose concentration was still considerably
below that expected when glucose consumption was
close to zero [indicated by the dashed line in Fig.
11(A)]. The presence of a sizable concentration gradient
between brain and plasma glucose implies that net glucose
uptake (i.e. glucose consumption at steady state) was
appreciable even under conditions close to isoelectricity.
The importance of measuring the brain glucose con-
centration can be appreciated from its role in regulating
brain glucose metabolism: glucose becomes rate-limiting
for metabolism when its concentration approaches that of
the Km of the first step in its metabolism, which is
phosphorylation by hexokinase. Since the Km of brain
hexokinase is very low (50mM) and NMR sensitivity in
vivo generally is too low to detect such small concentra-
tions of glucose, brain glucose concentrations measured
by NMR that are close to zero indicate that metabolism is
limited by the glucose available to the brain cell. The
general consensus is that brain glucose transport is not
rate-limiting for metabolism under normal circum-
stances. We have recently shown in the conscious human
and the -chloralose-anesthetized rat that the maximal
sustainable rate of glucose consumption is approximately
60–90% above the basal rate of glucose metabolism.21,24
This may, however, not be the case under conditions of
extreme metabolic activation or during hypoglycemia.
Previously, models of brain glucose transport have
been evaluated at normal or hyperglycemic conditions
only.21,22,115,129,130 A recent study extended the brain
glucose concentrations measurements to hypoglycemia
using 13C NMR spectroscopy.24 The concentrations mea-
sured by 13C NMR were found to be in excellent agree-
ment with those predicted by the reversible Michaelis–
Menten model as well as those measured by 1H NMR
spectroscopy [Fig. 11(B)]. Interestingly, when the brain
glucose concentration approached zero, CBF was acutely
increased 24 and glycogen degradation started,131 all of
which points to brain glucose being important in activat-
ing cerebral defenses against a deficiency in fuel supply.
Studies have reported that over a 45 min period of
forepaw stimulation, oxidative glucose metabolism was
increased by more than three-fold.112,132 Such an increase
in cerebral glucose metabolism is clearly beyond what
transport across the blood–brain barrier can sustain alone
and the implication is that other sources of fuel must have
been increasingly utilized.
BRAIN GLYCOGEN, THE FORGOTTEN
ENERGY STORE
One fuel source that is endogenous to the brain is
glycogen, which is present in the brain in measurable
quantities and appears to be essential for brain function.
However, the brain glycogen concentration is small
compared to the basal metabolic rate of the brain, even
though brain glycogen is typically present in quantities
that exceed those of tissue glucose in the brain. Textbook
reasoning has been that brain glycogen is unlikely to play
a role as a significant glucose reservoir, as it may be
consumed within minutes during, e.g. hypoglycemia.
However, during hypoglycemia, glycogen needs to ac-
count for only part of the total glucose metabolic rate and
hence can survive longer periods of sustained hypogly-
cemia. Similar to glucose, brain glycogen is rapidly
eliminated in post-mortem tissue,17,133,134 therefore, its
direct biochemical measurement is difficult. Recent stu-
dies suggest that, traditionally, brain glycogen content
may have been underestimated.135,136 Localized 13C
NMR spectroscopy has the unique capability of following
brain glycogen metabolism longitudinally, employing a
much smaller number of animals than would be used with
biochemical extraction. Our results showed that brain
glycogen indeed was only slowly degraded during hypo-
glycemia. This degradation started when brain glucose
approached zero [Fig. 12(A)] and became rate-limiting
for metabolism,131,137 as discussed above. Interestingly,
at this point cerebral blood flow was also increased
abruptly, indicating an attempt by the brain to increase
fuel supply for glycolysis, apparently by decreasing the
arterio-venous gradient for glucose.24 The rate of brain
glycogen degradation during hypoglycemia implied that
brain glycogen accounted for the majority of the glucose
supply deficit during the hypoglycemic period.131 To-
gether with the apparent stability of glycogen in the non-
stimulated brain at eu- or hyperglycemia,17,138 these data
suggest that brain glucose plays an important regulatory
role in cerebral glycogenolysis. These studies also showed
that brain glycogen increased above the basal level and
beyond following a single episode of hypoglycemia [Fig.
12(A)]. This rebound or super-compensation of brain
glycogen may result in increased neuroprotection. In this
context it is interesting to note that glycogen metabolism
also seems to be insulin-sensitive in the brain, as in most
tissues. Therefore, brain glycogen metabolism is likely to
be influenced by factors such as insulin and glucagon that
are known to be deranged in diabetes. It has been proposed
that brain glycogen metabolism may be a factor involved
in the mechanism of the hypoglycemia unawareness
syndrome observed clinically in patients with type I
diabetes,131,138 perhaps through the enhanced neuropro-
tective effect of increased brain glycogen.
Thus glycogen probably is a viable and important store
of glucose equivalents in the brain, whose metabolism is
affected by hormones, neurotransmitters and second
messengers.139
Studies have suggested that brain glycogen metabolism
may be altered during focal activation.140,141 Our studies
are consistent with a role for brain glycogen during
extreme activation for the following reason: under
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Figure 12. Brain glycogen metabolism in the rat. (A) Time-course of glycogen
C1 and glucose C1 before, during and after hypoglycemia, which was induced
by administering insulin, starting at the point indicated by the arrow. During
hypoglycemia, plasma glucose concentration was below 2 mM for 2 h. The
vertical dotted line indicates the start of glycogenolysis during hypoglycemia,
which coincided with the time point where brain glucose approached zero.
The dashed line highlights the slow rate of glycogenolysis during hypoglyce-
mia, expressed as percentages of the pre-hypoglycemic glycogen C1. From
Choi et al.131 Reprinted from J. Neurosci. Res. Copyright# John Wiley & Sons,
Ltd. (B) Label incorporation into glycogen and glucose C1, as well as several
metabolites was observed in a 13C NMR spectrum acquired from a rat brain
after 99% enriched [1-13C] glucose had been administered for over 48 h ad
libitum. Processing consisted of 10 Hz line-broadening and zero-filling prior to
Fourier transformation. The spectrum is shown without baseline correction.
(C) Comparison between label incorporation into brain glycogen C1 and NAA
C6 (solid circles) indicating slow turnover of brain glycogen in the awake rat.
The solid line indicates the result of linear regression (r¼0.93, p<0.01, n¼6).
From this relationship, total brain glycogen content was estimated at 3.3 mmol
glucosyl units/g wet weight. (B) and (C) are from Choi et al.138 Reprinted from
Neurochem. Int. Copyright# 2003, with permission from Elsevier
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conditions of extreme local glucose metabolic demand, it
is conceivable that the brain glucose concentration could
briefly fall into the range of the Km of hexokinase leading
to glycogenolysis and subsequent resynthesis at some
later time point. In this scenario, glucose must become
rate-limiting for metabolism, which can be inferred from
a study that reported during electrical stimulation of the
forepaw112,132 increases in oxidative glucose consump-
tion that were likely to exceed the sustainable supply in
brain glucose transport across the blood–brain barrier.
Anesthesia or depressed electrical activity have been
reported to have an effect on brain glycogen concentra-
tions.115,140,142 It has therefore been argued that small
changes in brain lactate during stimulation are due to a
futile cycling of glucose in and out of glycogen (brain
glycogen shunt),143 which would link brain glycogen
metabolism to brain activity, even when brain glucose
is not rate-limiting for metabolism. However, in the
awake rat brain, extremely slow rates of bulk brain
glycogen turnover were observed,138 as illustrated in
Fig. 12(B) and (C). These observations together with
the apparent influence of low brain glucose on glycogen-
olysis (see above) make this a rather unlikely scenario.
Nevertheless, during severe focal activation it is possible
that brain glycogen could in part be activated. Changes in
labeled glucose incorporation reported previously144 may
not reflect the entire glycogen molecule.
Because all previous studies measured brain glycogen
metabolism in animals, the question remained as to
whether brain glycogen metabolism may be faster in
the conscious human brain. Brain glycogen metabolism
has never been measured in the human brain and 13C
NMR is the only technique that can provide this insight.
We have recently adapted the localization method (see
above on localization methods and Fig. 5) for measuring
brain glycogen in humans and demonstrated that a
reproducible measurement of the brain glycogen signal
was indeed possible in the human brain18 [Fig. 13(A)].
These initial results furthermore demonstrated that brain
glycogen metabolism was extremely slow in subjects
measured in the awake, resting condition [Fig. 13(B)].
This observation was in excellent agreement with pre-
vious studies showing that, under the conditions of this
study (plasma glucose at euglycemia or higher with
concomitant hyperinsulinemia), the brain glucose con-
centration is well above the Km of hexokinase,
20,21,129
thereby eliminating the need for appreciable glycogen
activation. In fact, the flux through glycogen synthase at
hyperinsulinemia was estimated at 0.1–0.2mmol/g/h. As
a consequence, a brain glycogen pool of a few mM is
expected to have a turnover time on the order of several
days to a week. These findings suggest that glycogen
metabolism is a negligible factor in the energy metabo-
lism of the conscious unstimulated human brain at
euglycemia and above. Since concentration changes are
induced by a mismatch in catabolic and anabolic flux of
glycogen, it is, however, reasonable to assume that
elevated brain glycogen concentrations, such as the
ones seen after hypoglycemia in the rat, may take days
to weeks to be normalized, which incidentally is consis-
tent with the time it takes to restore the hypoglycemia
unawareness syndrome in diabetes.145
GLUTAMATE C4 TURNOVER: OXYGEN
METABOLISM
Because of the ever increasing importance of functional
MRI, which depends on an activation-dependent change
in the venous concentration of deoxyhemoglobin, the
question whether there is tight coupling between glucose
and oxygen consumption in the brain has become of
paramount importance. The landmark study by Fox and
Raichle in the late 1980s suggested that there is indeed a
large increase in glucose metabolism that exceeds the
Figure 13. Measurement of glycogen in the human brain.
(A) Demonstrates the detection of the brain glycogen signal
in four different subjects (arrows) along with the glucose C1
resonances. Shown is the spectral region containing the
glycogen C1 and glucose C1 resonances. (B) The increase
in the quantified glycogen C1 signal represents the accu-
mulation of [1-13C] glycogen, which occurred at an extre-
mely slow rate on the order of 0.15mmol/g/h in the human
brain, as illustrated in the graph containing measurements
from three different studies. From Oz et al.18 Reprinted
from Neurochem. Int. Copyright # 2003, with permission
from Elsevier
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changes in oxygen metabolism.146 The concept of un-
coupled oxygen metabolism has been supported by stu-
dies reporting small increases in brain lactate during focal
activation147,148 that initially were very controversial149
and that are very difficult to perform. The relatively small
magnitude of change in brain lactate is difficult to recon-
cile with the reported large uncoupling between oxygen
and glucose consumption150 and explanations linking the
lactate increase to brain glycogen at present appear
unlikely (see above). To address this question, it is useful
to measure the TCA cycle activity in the brain. Because
glucose is the dominant substrate for metabolism, the flow
of 13C label from glucose into the TCA cycle is likely to
reflect the cerebral oxygen consumption. In intact tissue
the transfer of 13C label into the glutamate pool has been
linked to TCA cycle flux. The effect of focal activation on
cerebral glutamate turnover thus is expected to reflect
cerebral oxygen metabolism, at least in part. Using hemi-
field activation, glutamate turnover was measured in the
activated hemisphere and simultaneously in a control area
placed symmetrically to the midline separating the two
brain hemispheres. Comparison of the rate of label in-
corporation indicated a significant difference between the
activated and the resting voxels. Modeling of the data
indicated that oxygen consumption increased at most by
30%, which is approximately half of the cerebral blood
flow increase measured using this stimulation paradigm.62
This study supports the idea that oxygen consumption
increases are less than the associated cerebral blood flow
increases, leading to a net decrease in deoxyhemoglobin
content during focal activation, which forms the basis of
blood-oxygen-level-dependent functional MRI.151 Other
studies have also reported changes in the glutamate C4
turnover rate in response to altered electrical activ-
ity.39,132,152 However, it has been noted in the heart that
the labeling of glutamate can change without a change in
oxygen consumption,153 which was explained by changes
in a subcellular isotope flux that contributes to the labeling
rate of glutamate, as discussed below.
THE IMPORTANCE OF THE MALATE–
ASPARTATE SHUTTLE IN REGULATING
CEREBRAL GLUCOSE METABOLISM AND
ISOTOPE FLUX
Measurements of Krebs cycle flux from the flow of label
from glucose C1 to glutamate C4 are inherently affected
by the assumptions made in the modeling. Of critical
importance in that regard is the fact that most amino acids
are located in the cytosol, whereas the reactions leading
to the scrambling of the label take place in the mitochon-
drion. Therefore, transport has to occur across the highly
charged inner mitochondrial membrane. It is likely that
the transport of glutamate (a charged amino acid, whose
transport is generally associated with concomitant ion
transport) or 2-oxoglutarate is controlled, since rapid
transport of these acids is likely to interfere with che-
miosmosis. Indeed, this exchange rate Vx was found to be
comparable to the flux through pyruvate dehydrogenase,
VPDH, in most recent studies of the intact brain,
9,115,154 as
illustrated by Fig. 14(A), consistent with what has been
reported in most other tissues.40,116,153,155 In the brain
and other tissues, isotope exchange can occur via the
malate-aspartate shuttle [illustrated by the scheme in
Fig. 14(B)]. The observation that Vx was comparable to
the flux through pyruvate dehydrogenase (Table 2) im-
plied that the malate–aspartate shuttle may be a major
mechanism mediating the exchange of label across the
mitochondrial membrane,156 also pointed out else-
where.9,53,153,157 Even transamination of glutamate may
not be a very fast reaction in vivo: some studies suggest
that the transamination rates in the brain are within one




Brain metabolism is exquisitely compartmentalized, with
at least two major compartments (attributed to the ‘neu-
ronal’ and ‘glial’ compartments) that are differentiated by
the size of the respective glutamate pools associated with
the Krebs cycle and that are metabolically linked by the
so-called glutamate-glutamine cycle.159,160 It has now
become accepted that the large glutamate pool is in the
neuronal compartment and the small glutamate pool in
the glial compartment.161,162 The compartmentation ex-
tends further to a number of enzymes, such as glutamine
synthetase163 and pyruvate carboxylase,164 being almost
exclusively in the glial compartment. Furthermore, gly-
cogen appears to be mainly in the glial compartment in
the normal adult brain.165 The compartmentation of brain
metabolism and associated enzymes is summarized in
more detail elsewhere.9,49,50 The scheme in Fig. 14(C)
summarizes some of the salient features that can be
exploited in modeling brain metabolism. It is of interest
to note that the exclusive glial localization of glutamine
synthetase implies that the observation of glutamine
synthesis in vivo, first achieved in the human brain,47,48
is a direct manifestation of glial metabolism, whereas the
observation of label incorporation into glutamate implies
a mainly neuronal event. Clearly, glutamine synthesis can
be measured non-invasively by 13C NMR spectroscopy,
as shown in Fig. 4, which demonstrates the ability of 13C
NMR spectroscopy to study cerebral compartmentation
non-invasively.
ASTROCYTIC ENERGY METABOLISM AND
ANAPLEROSIS
A key feature of cerebral compartmentation is the in-
activation of neurotransmitter glutamate by uptake into
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perisynaptic astrocytes and conversion into electrophy-
siologically inactive glutamine.158,166–168 Clearly, this
mechanism implies a much more active role for astro-
cytes than is conventionally assumed, since the conver-
sion of neurotransmitter glutamate to glutamine involves
glial energy metabolism.169–171 The neuron–astrocyte
pair thus has to be considered the functional unit (the
‘tripartite synapse’ containing the pre- and postsynaptic
neuron and the astrocyte) intimately involved in achiev-
ing chemical transmission, as has been proposed in the
last decade by Magistretti and others.52,172,173
The link between astrocytes and neurons is generally
accepted from a metabolic and from a neurophysiological
standpoint,174 yet differences exist as to the precise
relationship between the metabolic rates and the specific
energetics involved.9,39,115,175 For example, a recent
proposal suggested that the rate of glutamate/glutamine
inter-conversion (‘glutamate-glutamine cycle’), identi-
fied in the scheme in Fig. 14(C) by V
app
NT , is equal to the
glucose consumption rate.39 Our recent measurements
(summarized in Table 2) imply that, even when assuming
that changes in glutamate neurotransmission result in a
1:1 stoichiometric change of glucose metabolism with
V
app
NT (which is different from what has been proposed
39),
glucose metabolism at VNT¼ 0 (‘isoelectricity’) is ap-
proximately half of that at normal resting conditions,
which is in good agreement with reported rates of oxygen
consumption during isoelectric pentobarbital anesthesia
in humans.176 The proposal put forth by Shulman and co-
workers39,51 is intriguing as it emphasizes further the
coupling between neurons and glia at the level of energy
metabolism as put forward earlier by others.173
Astrocytes have significant oxidative capacity to gen-
erate ATP, which shall be illustrated with two experi-
mental observations. First, anaplerosis, a mitochondrial
reaction confined to the glial compartment, mediated by
pyruvate carboxylase, is now generally accepted to have
significant activity in vivo.8,9,31,69 Anaplerosis occurs in
the glial compartment and labels the TCA cycle inter-
mediates in a different way than does pyruvate dehydro-
genase. If pyruvate carboxylase was a substantial flux,
VPC, in the brain in vivo, this should result in a differential
labeling of glutamate and glutamine due to their differ-
ential distribution between astrocytes and neurons. In-
deed, it was concluded from the differential label
distribution in glutamate and glutamine (Table 3) that
pyruvate carboxylase activity was substantial8,9,31,33 and
contributed approximately 25% to the flux through glu-
tamine synthetase Vsyn,
8 which was comparable to the
numbers subsequently reported in the rat brain using
[2-13C] glucose infusions.89 Net glutamine synthesis
(via pyruvate carboxylase) was shown to generate excess
amounts of ATP oxidatively, thereby generating approxi-
mately one-third of the ATP per glucose molecule com-
pared to that from complete glucose oxidation.53 The
second experimental evidence supporting the presence of
significant oxidative metabolism in astrocytes stems from
the fact that acetate is known to be exclusively metabo-
lized in astrocytes by the TCA cycle,177,178 which can
Table 2. Relative fluxes in human visual cortex
(mean SE) as measured by 13C NMR following glu-




Oxidative ATP/total ATP production in glia 80 5%
Glial/neuronal ATP synthesis 16 9%
Vx/VPDH 100 35%
a For a definition of fluxes see Fig. 14(C) and Gruetter et al.9
Table 3. Label incorporation into glutamine (Gln)
relative to glutamate (Glu) in human visual cortex as
measured by 13C NMR following glucose infusion
(meanSEM)
C2 C3 C4
Gln/Glu 0.41 0.02 0.28 0.04* 0.30 0.01
(45 ml volume9)
Gln/Glu 0.39 0.03 0.18 0.01* 0.26 0.02
(72 ml volume8)
* Significantly different between C2 and C3 ( p< 0.05).
3—————————————————————————————————————————
Figure 14. Modeling of cerebral neurotransmitter and amino acid metabolism labeling from glucose. (A) Direct experimental
evidence of a slow exchange between 2-oxoglutarate and glutamate in vivo by comparing the rate of labeling for the C3 and
the C4 of glutamate. The solid line indicates calculation using the parameters from Choi et al.115 The dashed line was calculated
after fitting to the 13Glu4(t) and
13Gln4(t) data only, which resulted in VPDH¼0.15 mmol/g/min when assuming Vx¼ 57 mmol/g/
min, as in Sibson et al.39, but this was clearly inconsistent with the relative rate of labeling of the C3 resonance in glutamate. (B)
The link between oxidative glucose consumption and glutamate labeling is established by active exchange between 2-
oxoglutarate (OG) and glutamate (Glu), this flux is indicated by Vx. This exchange, as well as that between oxaloacetate and
aspartate, is mediated by the malate-aspartate shuttle.53 In short, the NADH produced by oxidative metabolism of pyruvate at
the rate VPDH must be recycled. This is accomplished by the malate-aspartate shuttle, which transports reducing equivalents
produced from the cytosol to the mitochondrion, indicated by the fluxes. The solid lines indicate the isotope flow between the
TCA cycle and the cytosolic amino acids, the dashed lines the oxidative metabolism of pyruvate, the dotted lines the NADH/
NADþ redox reaction, and the subscripts the flow of label from glucose C1 (or C6) to glutamate. (C) A mathematical model of
compartmentalized brain metabolism, from Gruetter et al.53 Reprinted from Neurochem. Int. Copyright # 2003, with
permission from Elsevier. The glial compartment is on the left and the neuronal on the right. Abbreviations for metabolic fluxes:
VgþVPC, glial pyruvate dehydrogenase flux; Vefflux, loss of Gln from the glial compartment; Vout, VLout, label dilution and
exchange of lactate across the blood–brain barrier. The metabolites in bold are the signals measurable by NMR in vivo. The
subscripted numerals indicate the positions labeled due to metabolism of glucose labeled at the C1 position, i.e. Glc1
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only occur by oxidative metabolism.179 Interestingly, the
metabolic rates of the glial compartment relative to the
neuronal compartment reported from the acetate studies
in the human brain71,87 confirmed the earlier measure-
ment of relative glial ATP synthesis in the human brain,9
tabulated in Table 2.
The mainly oxidative glial metabolism is compatible
with the proposal that lactate produced in astrocytes is a
fuel for oxidative metabolism in neurons. For example, if
one-sixth of the ATP production from glucose is in the
glial compartment, five-sixths of the lactate remain for
export to neurons, when assuming the extreme case that
phosphorylation of glucose is an exclusively glial process.
OUTLOOK
As illustrated above and summarized in the abstract,
localized 13C NMR spectroscopy has already made
many substantial contributions to our understanding of
brain metabolism, e.g. understanding glucose transport,
measuring brain glutamate and glutamine turnover, quan-
tifying astrocytic and brain glycogen metabolism. Pivotal
achievements include the demonstration that pyruvate
carboxylase activity is substantial in vivo, and that
glutamatergic neurotransmission can potentially be quan-
tified in vivo. Future developments on the technical side
probably will include the extension of these studies to
GABA metabolism in vivo, and the characterization of
the various fluxes that can be measured in different brain
areas. Some investigators have already begun applying
13C NMR spectroscopy to disease states in humans88,123
and animal models of disease,154 and future expansion is
to be expected in this area as well. The low sensitivity and
technical complexity, including the administration of 13C
label, will probably remain obstacles that need to be
overcome for a successful 13C NMR line of research. The
most important issue for this field to flourish, however, is
the emergence of a critical mass of several independent
research groups whose competition will foster the devel-
opment of this new investigative tool of localized in vivo
13C NMR spectroscopy.
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